Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The study evaluated imlunestrant as a monotherapy and in combination with abemaciclib in patients with ER-positive, HER2-advanced breast cancer who had previously received endocrine therapy.

Yoshida's laboratory focuses on determining molecular mechanisms involved in the regulation of gene expression and signal transduction pathways in cancer development and drug resistance by using high ...

More information: Komal L. Jhaveri et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2410858 ...